Objective: This study assessed postoperative complication rates for hysterectomy routes years after the U.S. Food and Drug Administration (FDA) statement warning against power morcellators use. Materials and Methods: The American College of Surgeons National Surgical Quality Improvement Program® database was used to evaluate hysterectomies performed prestatement (2009–2013) and poststatement (2015–2019). Primary outcomes were 30-day postoperative complication which were categorized as overall, major and minor complications. A secondary outcome was route of hysterectomy. A subanalysis was performed for fibroid hysterectomies. Results: Prestatement versus poststatement complication rates, respectively, were as follows. In 309,783 hysterectomies for benign indications, overall: 9.4% versus 8.9% (adjusted odds ratio [aOR]: 0.92; 95% confidence interval [CI]: 0.89, 0.94]); major: 3.5% versus 3.3% (aOR: 0.95: 95% CI: 0.90, 0.99); and minor: 6.9% versus 6.4% (aOR: 0.89; 95% CI: 0.86, 0.92) complication rates were significantly lower in the poststatement period. There was an increase in laparoscopic (51.4% versus 59.3%) and decreases in open (27.0% versus 21.7%) and vaginal (21.7% versus 19.0%) approaches. In 96,985 hysterectomies for fibroids, complication rates were unchanged with overall: 9.4% versus 9.5% (aOR: 0.97; 95% CI:, 0.92, 1.03); major: 3.1% versus 3.2% (aOR: 0.98; 95% CI: 0.89, 1.07); and minor: 7.1% versus 7.2% (aOR: 0.98; 95% CI: 0.92, 1.04) complications, with a similar increase in laparoscopic (50.9% versus 55.5%) and a decrease in open (41.5% versus 37.7%) and vaginal (7.7% versus 6.8%) approaches. Conclusions: Years after the FDA statement, postoperative complication rates have decreased for benign hysterectomies and remain unchanged for fibroid hysterectomies with rising rates of laparoscopic hysterectomies. While there may have been an increase in complications and open surgeries after the statement, these trends were transient and have reversed. (J GYNECOL SURG 40:32) [ABSTRACT FROM AUTHOR]